Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs.
A number of drugs have been studied for their effect on the metabolism of the antimalarial drug mefloquine by human liver microsomes (N = 6) in vitro. The only metabolite generated was identified as carboxymefloquine by co-chromatography with the authentic standard. Ketoconazole caused marked inhibition of carboxymefloquine formation with IC50 and Ki values of 7.5 and 11.2 microM, respectively. The inhibition of ketoconazole, a known inhibitor of cytochrome P450 isozymes, and the dependency of metabolite formation on the presence of NADPH indicated that cytochrome P450 isozyme(s) catalysed metabolite production. Of compounds actually or likely to be coadministered with mefloquine to malaria patients only primaquine and quinine produced marked inhibition (IC50, 17.5 and 122 microM; Ki, 8.6 and 28.5 microM, respectively). However, despite these in vitro data with primaquine, clinical studies have failed to show any significant effect of single dose primaquine on the pharmacokinetics of mefloquine. With quinine, because peak plasma concentrations are very close to the Ki value, there is likely to be inhibition of mefloquine metabolism in patients receiving both drugs. Sulfadoxine, artemether, artesunate and tetracycline did not significantly inhibit carboxymefloquine formation.
Bangchang
K N
KN
Department of Pharmacology and Therapeutics, University of Liverpool, U.K.
Karbwang
J
J
Back
D J
DJ
D001711:Biotransformation / Q000187:drug effects; D065607:Cytochrome P-450 Enzyme Inhibitors; D006801:Humans; D007654:Ketoconazole / Q000494:pharmacology; D007700:Kinetics; D015767:Mefloquine / Q000378:metabolism* / Q000494:pharmacology; D008862:Microsomes, Liver / Q000378:metabolism*; D011319:Primaquine / Q000494:pharmacology; D011803:Quinine / Q000494:pharmacology
D065607:Cytochrome P-450 Enzyme Inhibitors; D011803:Quinine; D011319:Primaquine; D007654:Ketoconazole; D015767:Mefloquine